GlaxoSmithKline (LON:GSK) Rating Reaffirmed
The equities firm has just set a target price per share of GBX 1450 on GlaxoSmithKline (LON:GSK) shares. This is 8.01% from the last stock close. In a note shared with investors and clients on Friday morning, Morgan Stanley reiterated their Equalwt/In-Line rating on shares of GSK.
From a total of 24 analysts covering GlaxoSmithKline PLC (LON:GSK) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is GBX 1800 while the lowest target price is GBX 1250. The mean of all analyst targets is GBX 1477.54 with a 9.87% above today’s (GBX 1341) stock price. GlaxoSmithKline PLC was the topic of 97 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on December 10 with “Market Perform” rating. Goldman Sachs maintained shares with “Buy” rating and GBX 1800 target share price in a report from a November 24. Jefferies maintained GSK stock in a recent report from December 7 with “Hold” rating. J.P. Morgan maintained the rating on November 20. J.P. Morgan has a “Neutral” rating and a GBX 1370 price target on shares. Finally, Morgan Stanley maintained the stock with “Equal-Weight” rating in a report issued on a December 2.
Approximately 3.53M shares of stock traded hands. GlaxoSmithKline plc (LON:GSK) has declined 7.51% since May 21, 2015 and is downtrending. It has underperformed by 3.71% the S&P500.
GlaxoSmithKline plc. is a healthcare firm that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The company has a market cap of 64.14 billion GBP. The Firm operates in two divisions: Pharmaceuticals and Vaccines, and Consumer Healthcare. It has 6.59 P/E ratio. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.
According to Zacks Investment Research, “GlaxoSmithKline is one of the world’s leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.”